Pelthos Therapeutics Inc. [PTHS] - / Public Company merger
Pelthos Therapeutics Inc. will merge with Public Company, becoming a wholly-owned subsidiary, as part of a two-step merger process detailed in the definitive merger agreement.
Why this matters
Pelthos Therapeutics Inc., a company specializing in dermatological treatments and gene-modified cell therapies, is set to merge with Castle Creek Biosciences. Castle Creek is known for its late-stage fibroblast-based platform and its lead candidate, D-Fi, which targets dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder. This merger aims to create a transformative biotechnology company that combines Pelthos's established commercial capabilities with Castle Creek's innovative technologies. Upon completion, the combined entity will continue to operate under the Pelthos Therapeutics name and trade on the NYSE American under the ticker symbol PTHS.